Abstract:Abstract Programmed cell death-1 (PD-1) is a co-inhibitory protein that dampens TCR/CD28 signaling in part by recruiting the phosphatase SHP2 to the immunological synapse. Chronic antigenic restimulation of T cells can induce apoptosis or elicit PD-1-mediated exhaustion, rendering them hyporesponsive and ineffectual. While the checkpoint function of PD-1 has profound implications for cancer immunotherapy, the role of PD-1 in conventional effector T cell responses remains unclear. Restimulation-induced cell death (RICD) is a critical propriocidal apoptosis program triggered in activated T cells upon robust TCR re-engagement, constraining effector T cell expansion and longevity to prevent collateral tissue damage. We hypothesized that PD-1 attenuates RICD sensitivity in human effector T cells by modulating TCR signal strength. Here we show that transient upregulation of PD-1 helps to protect newly activated human CD4+ and CD8+ T cells from premature RICD during clonal expansion, with lesser effects noted in terminally differentiated T cells. Both antibody-mediated blockade of PD-1-PD-L1 and SHP2 inhibition increased RICD sensitivity to a similar extent. Conversely, concomitant addition of recombinant PD-L1 with TCR restimulation significantly reduced RICD in a dose-dependent manner, with more pronounced protection noted uopn CD28 coligation. Our ongoing work aims to define the role of recently discovered downstream PD-1 signaling nodes (e.g. PAG, VRK2) and specific pro/anti-apoptotic proteins in this process. These findings present significant implications for understanding how PD-1 blockade may influence apoptosis sensitivity in both normal and exhausted T cells to alter adaptive immune responses. Supported by grants from NIH (R35GM139619)

CRISPR-Cas9 mediated efficient PD-1 disruption on human primary T cells from cancer patients

CRISPR-Cas9 Mediated Efficient PD-1 Disruption on Human Primary T Cells for Adoptive Therapy

Crispr-Cas9 Mediated Efficient Pd-1 Disruption On Human Primary T Cells From Cancer Patients (Vol 6, 20070, 2017)

Engineered triple inhibitory receptor resistance improves anti-tumor CAR-T cell performance via CD56

CRISPR/Cas9-mediated PD-1 Disruption Enhances Human Mesothelin-Targeted CAR T Cell Effector Functions.

Engineered Cells for Costimulatory Enhancement Combined with IL-21 Enhance the Generation of PD-1-disrupted CTLs for Adoptive Immunotherapy.

Effect of CRISPR/Cas9-Edited PD-1/PD-L1 on Tumor Immunity and Immunotherapy

Photo‐Enhanced CRISPR/Cas9 System Enables Robust PD‐L1 Gene Disruption in Cancer Cells and Cancer Stem‐Like Cells for Efficient Cancer Immunotherapy

Dual‐Locking Nanoparticles Disrupt the PD‐1/PD‐L1 Pathway for Efficient Cancer Immunotherapy

CRISPR-Cas9-mediated Disruption of PD-1 on Human T Cells for Adoptive Cellular Therapies of EBV Positive Gastric Cancer.

Time-programmed activation of CD47 disruption and immunogenic cell death with Cas9 ribonucleoprotein nanocapsule for improved cancer immunotherapy

Programmable Unlocking Nano‐Matryoshka‐CRISPR Precisely Reverses Immunosuppression to Unleash Cascade Amplified Adaptive Immune Response

PD-1 blocking strategy for enhancing the anti-tumor effect of CAR T cells targeted CD105

PD-1/PD-L1 Checkpoint Inhibitors in Tumor Immunotherapy

Correction: Corrigendum: CRISPR-Cas9 mediated efficient PD-1 disruption on human primary T cells from cancer patients

Exclusion of PD-1 from the immune synapse: A novel strategy to modulate T cell function

Aptamer/Peptide‐Functionalized Genome‐Editing System for Effective Immune Restoration through Reversal of PD‐L1‐Mediated Cancer Immunosuppression

PD-1 regulation in immune homeostasis and immunotherapy

Peripheral blood–derived PD-1/CD28–CD19-CAR–modified PD-1+ T-cell therapy in patients with solid tumors

PD-1 protects expanding human T cells from premature restimulation-induced cell death.

Activated T cell-derived exosomal PD-1 attenuates PD-L1-induced immune dysfunction in triple-negative breast cancer